Perflenapent emulsion - NuvOx Pharma
Alternative Names: NanO2™ emulsionLatest Information Update: 28 Jul 2024
At a glance
- Originator Achieve Life Sciences
- Class Anti-ischaemics; Antianaemics; Antihaemorrhagics; Antineoplastics; Fluorocarbons; Neuroprotectants; Radiation-sensitising agents; Radiosensitisers; Small molecules; Vascular disorder therapies
- Mechanism of Action Oxygen carriers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypoxic respiratory failure
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Hypoxic-respiratory-failure in USA (IV, Infusion)
- 30 Jun 2020 Preclinical trials in Hypoxic respiratory failure in USA (IV) before June 2020 (NuvOx Pharma pipeline, July 2020)
- 30 Jun 2020 Health Canada approves clinical trial application for dodecafluoropentane emulsion in Hypoxic respiratory failure